Advancing a novel approach to obesity for better outcomes

We are harnessing the power of activin biology to develop therapeutics for obesity and cardiometabolic disease.

Our clinically-validated lead candidate, bimagrumab, is a potent, first-in-class monoclonal antibody that blocks activin type II receptors, directly targeting fat and muscle tissue, and shows promise for significant and lasting impact in patients with obesity and cardiometabolic diseases.

Bimagrumab is poised to usher in a new treatment paradigm—first for obesity, and then more broadly across cardiometabolic diseases.